Makers Laboratories working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
129.41×146.91×117.92×109.58×
40.72×50.30×52.42×64.60×
96.99×129.83×91.80×61.34×
73.14×67.38×78.54×112.84×
0.69×0.55×0.57×0.50×
1.18×—0.44×0.22×
−2.77×0.72×0.81×0.34×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MAKERSL₹192.45

Makers Laboratories Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹114 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Inventory Days (DIO)109.58117.92146.91129.41
Receivable Days (DSO)64.6052.4250.3040.72
Payable Days (DPO)61.3491.80129.8396.99
Cash Conversion Cycle (days)112.8478.5467.3873.14
Asset Turnover0.500.570.550.69
Cash Conversion (CFO/Net Income)0.220.44—1.18
CFO/EBITDA0.340.810.72-2.77
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.